Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Companyâs pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļIRD
āļāļ·āđāļāļāļĢāļīāļĐāļąāļOpus Genetics Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļNov 30, 2004
āļāļĩāļāļĩāđāļMagrath (George)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ18
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļNov 30
āļāļĩāđāļāļĒāļđāđ8 Davis Drive
āđāļĄāļ·āļāļDURHAM
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ27713
āđāļāļĢāļĻāļąāļāļāđ12486819815
āđāļ§āđāļāđāļāļāđhttps://opusgtx.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļIRD
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļNov 30, 2004
āļāļĩāļāļĩāđāļMagrath (George)
Dr. George Magrath
Chief Executive Officer, Director
Chief Executive Officer, Director
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Chief Financial Officer
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Mr. Sean Ainsworth
Independent Director
Mr. Bernhard Hoffmann
Senior Vice President - Corporate Development and Operations
Senior Vice President - Corporate Development and Operations
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Dr. Ashwath (Ash) Jayagopal, Ph.D.
Dr. Ashwath (Ash) Jayagopal, Ph.D.
Chief Scientific and Development Officer
Chief Scientific and Development Officer
Dr. Benjamin R. Yerxa, Ph.D.
Dr. Benjamin R. Yerxa, Ph.D.
President, Director
Mr. Joseph K. (Joe) Schachle
Mr. Joseph K. (Joe) Schachle
Chief Operating Officer
Mr. Ronil Patel
Chief Business Officer
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. George Magrath
Chief Executive Officer, Director
Chief Executive Officer, Director
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Chief Financial Officer
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Mr. Sean Ainsworth
Independent Director
Mr. Bernhard Hoffmann
Senior Vice President - Corporate Development and Operations
Senior Vice President - Corporate Development and Operations
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director